Abstract: This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof ##STR1## wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl;R.sup.1 is alkyl;R.sup.2 represents alkyl from 1 to 5 carbon atoms, aryl or aryl substituted with halogen or alkyl from 1 to 5 carbon atoms;R.sup.6 is alkyl;n is 1 to 5;p is 0 to 6;x is 0 or 2; andR.sup.4 and R.sup.5 are independently hydrogen or alkyl or together with N form a cycloalkylamine.The compounds of Formula I are leukotriene B.sub.4 antagonists and are useful as anti-inflammatory agents and in treating disease conditions mediated by LTB.sub.4.

Abstract: The present invention provides breast cancer chemopreventive arylamide analogues of retinoic acid, more particularly C-glycoside analogues of N-(4-hydroxyphenyl)retinamide-O-glucuronide and N-glycoside analogue of retinoyl .beta.-glucuronide that resist both .beta.-glucuronidase mediated enzymatic hydrolysis as well as acid catalyzed hydrolysis. Specifically, the drugs include 4-(retinamido)phenyl-C-glucuronide; 4-(retinamido)phenyl-C-glucoside; 4-(retinamido)benzyl-C-xyloside; 4-(retinamido)benzyl-C-glucoside; 4-(retinamido)benzyl-C-glucuronide; 4-(retinamido)phenyl-C-xyloside, 1-(B-D-glucopyranosyl) retinamide and 1-(D-glucopyranosyluronosly) retinamide. The invention also relates to a method for making such drugs.

Abstract: Provided is a method of inhibiting estrogen activity by administering a biologically active amount of a substituted dibenzofuran or substituted dibenzodioxin.

Abstract: The present invention is based upon the discovery that the methanol extract of the bryozoan Myriapora truncata showed potent cytotoxicity against L1210 murine leukemia cells (99% inhibition at 50 .mu.g/mL). Fractionation and purification of active components from this extract, guided by a cytotoxicity assay, resulted in the isolation of a novel, highly cytotoxic polyketide-derived metabolite MT-332 (Compound 3) and its equilibrium isomer (Compound 4), along with two less active compounds, MT-381 (Compound 1) and MT-381-B (Compound 2). The equilibrium mixture of Compounds 3 and 4 showed 88% inhibition at 0.2 .mu.g/mL against L1210 cells.

Abstract: Described are novel reversible photochromic phenanthropyran compounds, examples of which are substituted 2H-phenanthro 4,3-b!pyran and 3H-phenanthro 1,2-b!pyran compounds. The 2H-phenanthropyran compounds have certain substituents at the number 5 and 6 carbon atoms of the phenanthro portion of the phenanthropyran and at the 2 position of the pyran ring. Certain substituents may also be present at the number 7, 8, 9, 10, 11, or 12 carbon atoms of the phenanthro portion of the phenanthropyran. The 3H-phenanthropyran compounds have certain substituents at the number 11 and 12 carbon atoms of the phenanthro portion of the phenanthropyran and at the 3 position of the pyran ring. Certain substituents may also be present at the number 5, 6, 7, 8, 9, or 10 carbon atoms of the phenanthro portion of the phenanthropyran. Also described are polymeric organic host materials that contain or that are coated with such compounds.

Abstract: The present invention is directed to two novel compounds isolated from a Pacific sponge, Plakortis (Homosclerophorida, Plakinidae) which are designated herein as epidioxymanadic acids A and B. These two compounds have been obtained by a bioassay-guided (i.e., antibiotic activity) isolation procedure, involving solvent partition and chromatography on Sephadex LH-20, cyano, and C-18 columns, from extracts of sponge.

Abstract: This invention provides novel compounds and pharmaceutical methods comprising the administration of a compound of the Formula I: ##STR1## wherein n, m, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are variables.

Abstract: Disclosed is an improved process for the preparation of tocopherol concentrates from vegetable oil distillates. Tocopherol concentrates are obtained containing 20-80% tocopherol by weight, with an overall recovery of tocopherol of 72% to 97%. The process is comprised first of an esterification reaction where the more volatile alcohols are converted to their less volatile fatty acid esters, followed by a series of distillation steps where components boiling higher and lower than the tocopherols are separated from tocopherols and other like boiling substances. Advantages of the process are that tocopherol concentrates are produced efficiently and economically in a minimum number of steps without the use of solvents and with a relatively small capital investment.

Abstract: New substituted phenoxyisobutyric acids and esters that can be used as medicaments and correspond to the formula: ##STR1## wherein X, A, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the description.Those compounds and their physiologically tolerable salts can be used therapeutically.

Abstract: Process for the preparation of olefins by using a palladium catalyst at a temperature above the ceiling temperature of the SO.sub.2 /olefin copolymer system, for the synthesis of sulfinic and sulfonic acid derivatives.

Abstract: The invention is antiobesity/antidiabetic/beta-3 agonists of the formula ##STR1## wherein the substituents R.sub.o, R.sub.1, R.sub.4, R.sub.4 ', R.sub.5, R.sub.6 or n are as defined in the specification.

Abstract: A process for preparing a dialkali metal cromoglycate which comprises (1) condensing a hydroxy substituted ketone with a condensing agent in the presence of a base material and an organic solvent; (2) subjecting the condensed material to ring-closure conditions, first in the presence of an alkali metal alkoxide and a suitable organic solvent, then followed by the addition of substantially dry mineral acid and a suitable organic solvent; and (3) hydrolyzing the ring-closed material in the presence of a base material and a suitable organic solvent to form said cromoglycate.

Abstract: Benzopyran derivatives which have an inhibitory effect on the Maillard reaction as well as an antioxidizing effect are described herein. These derivatives may be utilized in the treatment and/or prevention of diabetic complications such as, for example, coronary heart disease, peripheral circulatory insufficiency or failure, cerebrovascular hindrance, neurogenous diabetes, nephropathy, arteriosclerosis, arthrosclerosis, cataracts and retinopathy. Further, the derivatives may also be used in the treatment and/or prevention of diseases induced by aging and in the treatment and/or prevention of diseases caused by the formation of peroxidized fat.

Abstract: An (S)-1-phenyl-2-substituted propane derivative shown by the following formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent a lower alkyl group, etc., or R.sup.1 and R.sup.2 may form together an alkylene group, etc.; R.sup.3, R.sup.4 and R.sup.5 represent a hydrogen atom, etc.; and X represents a hydroxyl group which may be protected with a protective group, or a halogen atom etc., can readily be produced (i) by permitting a microorganism belonging to the genus Torulaspora, the genus Candida, the genus Pichia or the like to act on a phenylacetone derivative and asymmetrically reducing the compound, or (ii) by sterically inverting an (R)-enantiomer. (R,R)-1-phenyl-2-[(2-phenyl-1-methylethyl)amino]ethanol derivative having a high optical purity can easily be obtained from the compound of the formula (I). The ethanol derivative is useful as an anti-obesity agent and the like.

Abstract: Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthetase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.

Abstract: A method for resolving racemic dimethyl-4,4'-dimethoxy-5,6,5',6'-di(methylenedioxy)biphenyl-2,2'-dicarbox ylate ("DDB"), in which a chiral .alpha.-alkyl benzyl alcohol is used as the resolving agent. More specifically, racemic DDB is first hydrolyzed to form dicarboxylic acid, which is then reacted with chiral .alpha.-alkyl benzyl alcohol to form two chiral isomers. The chiral isomers, after separation either by chromatography or by recrystalli-zation, are respectively hydrogenated and esterified to form chiral DDB isomers.

Abstract: New biotenside esters and phosphatides formed with Vitamin-D and Vitamin-E compounds possessing a pronounced antitumor activity, processes for their production as well as for the preparation of concentrates and pharmaceutical compositions containing these new esters and phosphatides, and their use for treating tumors are described.

Abstract: A compound that can be converted, at a low cost and in a simple way, into 2-aryl-1,3-propanediols serving as precursors for synthesizing felbamate acting as an antiepileptic has a structure represented by Formula (1): ##STR1## wherein Ar represents an aryl group; R.sup.1 represents a hydrogen atom or is R.sup.4 or R.sup.5, where R.sup.4 represents an alkoxy group having 1 to 10 carbon atoms and R.sup.5 represents a hydroxy group or an acyloxy group having 1 to 10 carbon atoms; and R.sup.2 and R.sup.3 are hydrogen atoms at the same time or R.sup.2 and R.sup.3 together form a group represented by Formula (2): ##STR2## wherein R.sup.6 and R.sup.7 each independently represent a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, or R.sup.6 and R.sup.7 together form an oligomethylene group having 2 to 10 carbon atoms.

Abstract: This invention relates to quaternary ammonium salts of certain 2H-1-benzopyran derivatives, to the intermediates and processes useful for their preparation, to their free-radical scavenger and cellular protective properties and to their end-use application as therapeutic agents.

Abstract: The invention relates to a process for the preparation of 5-(1-hydroxy-2-urethanethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione derivatives, which are precursors of chiral tetramic acid derivatives.According to this process, an N-urethane-protected .alpha.-amino acid N-carboxy-anhydride is reacted with Meldrum's acid in an inert organic solvent medium in the presence of a tertiary amine.This process makes it possible to conserve the chirality of the starting material and in particular to simplify the synthesis of 4-amino-3-hydroxy acids and the derivatives thereof via the tetramic acid route.